stockrow
Friday 6 November 2026
Export ETON’s income statement to Excel — free account
Eton Pharmaceuticals, Inc.
ETON Healthcare Drug Manufacturers Specialty & Generic
Eton Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.0 million, up 104.9% from fiscal 2024.
- Revenue
- +157.9%
- EPS
- +1,857.1%
- Free cash flow
- +172.6%
- Total debt
- −24.0%
Quarter to September 2026, against a year earlier
54.21
7.06
+14.97%
Follow ETON
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
29.09 | 77.02 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
10.46 | 9.48 | 7.75 | 5.69 | |
P/FCF ratio |
73.81 | 0.00 | 0.00 | 220.99 | |
P/Operating CF |
41.88 | 137.92 | 90.94 | (39.39) | |
P/B ratio |
16.98 | 21.48 | 22.00 | 17.40 | |
Price to Tangible BV |
34.61 | 1,103.24 | 0.00 | 0.00 | |
EV/Sales |
10.23 | 9.49 | 7.87 | 5.75 | |
EV/EBITDA |
31.15 | 46.63 | 101.83 | 117.97 | |
EV/Operating CF |
37.63 | 66.18 | 43.21 | 43.67 | |
EV/FCF |
72.18 | (119.42) | (88.88) | 223.23 | |
Quick Ratio |
1.52 | 1.15 | 0.75 | 0.98 | |
Current Ratio |
1.79 | 1.52 | 1.21 | 1.57 | |
Net Debt/EBITDA |
(1.32) | 0.07 | 3.03 | 1.26 | |
Debt/Assets |
14.67% | 24.09% | 31.47% | 33.17% | |
Debt/Equity |
0.27 | 0.60 | 1.00 | 1.17 | |
Asset Turnover |
1.08 | 0.97 | 0.96 | 0.95 | |
Operating CF/Net income |
1.00 | 0.63 | 4.77 | (7.79) | |
Capex/Depreciation |
(1.96) | 0.00 | (12.07) | (0.04) | |
Interest Coverage |
35.08 | 11.89 | 2.87 | — | |
Research and Development Expense of Revenue |
9.10% | 2.64% | 7.73% | 8.36% | |
Selling, General and Administrative Expense of Revenue |
27.65% | 30.93% | 43.05% | 41.61% | |
Intangible Assets out of Total Assets |
0.28 | 0.39 | 0.45 | 0.34 | |
Share Based Compensation of Revenue |
5.71% | 3.91% | 6.26% | 5.28% | |
Graham Net Nets |
0.02 | 0.00 | (0.02) | (0.01) | |
Graham Number |
10.99 | 4.22 | 0.00 | 0.00 | |
Earnings Yield |
3.44% | 1.30% | (0.20%) | (1.01%) | |
Free Cash Flow Yield |
1.35% | (0.84%) | (1.14%) | 0.45% | |
Revenue per Share |
2.02 | 1.36 | 0.89 | 0.79 | |
Operating CF per Share |
1.23 | 0.26 | 0.27 | (0.43) | |
Capex per Share |
(0.11) | 0.00 | (0.55) | 0.00 | |
Free Cash Flow per Share |
1.12 | 0.26 | (0.28) | (0.43) | |
Cash per Share |
1.94 | 0.97 | 0.72 | 0.96 | |
Shareholders Equity per Share |
3.03 | 1.69 | 1.12 | 0.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.03 | 1.69 | 1.12 | 0.97 | |
Free Cash Flow |
32.00 | 7.26 | (7.67) | (11.60) | |
Working Capital |
42.69 | 23.48 | 9.07 | 22.09 | |
Capital Expenditures |
(3.24) | 0.01 | (15.07) | (0.05) | |
Net Current Asset Value |
26.43 | (0.62) | (13.85) | (5.38) | |
EV/EBIT |
35.47 | 61.42 | 335.53 | 0.00 | |
Capex to Sales |
0.06 | 0.00 | 0.62 | 0.00 | |
Price to Operating Income |
36.27 | 61.36 | 330.10 | 0.00 | |
| Other line items | |||||
Average Receivables |
19.75 | 19.67 | 14.90 | 8.56 | |
Average Payables |
15.38 | 13.27 | 9.18 | 7.57 | |
Average Inventory |
13.97 | 16.97 | 14.04 | 15.33 | |
Average Assets |
130.89 | 108.74 | 90.87 | 84.12 | |
Average Common Equity |
55.02 | 35.27 | 27.53 | 25.29 |
Columns are period end dates · fundamentals updated 5 Nov 2026